Format

Send to

Choose Destination
  • This is a preview / test site. Please update your PubMed URL to pubmed.gov.
See comment in PubMed Commons below
Lancet. 2009 Dec 19;374(9707):2115-2122. doi: 10.1016/S0140-6736(09)61877-8. Epub 2009 Oct 31.

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Author information

  • 1Center for Global Health and Division of Infectious Diseases, Cincinnati Children's Hospital, Cincinnati, OH, USA. Electronic address: Steven.Black1@cchmc.org.
  • 2National Institute for Health and Welfare, Helsinki, Finland.
  • 3Center for Vaccinology and Neonatal Immunology, Department of Pediatrics, University of Geneva, Geneva, Switzerland.
  • 4Institute for Vaccine Safety, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • 5Division of Infectious Diseases, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
  • 6Vaccine Safety Section, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON, Canada.
  • 7Health Protection Agency, Centre for Infections, Colindale, London, UK.
  • 8National Vaccine Program Office, Department of Health and Human Services, Washington, DC, USA.
  • 9Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA.
  • 10Discipline of Paediatrics, School of Paediatrics and Reproductive Health, University of Adelaide, SA, Australia.
  • 11Department of Pediatrics, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
  • 12Quality, Safety and Standards Team, World Health Organization, Geneva, Switzerland.
  • 13Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Erratum in

  • Lancet. 2010 Jan 30;375(9712):376.

Abstract

Because of the advent of a new influenza A H1N1 strain, many countries have begun mass immunisation programmes. Awareness of the background rates of possible adverse events will be a crucial part of assessment of possible vaccine safety concerns and will help to separate legitimate safety concerns from events that are temporally associated with but not caused by vaccination. We identified background rates of selected medical events for several countries. Rates of disease events varied by age, sex, method of ascertainment, and geography. Highly visible health conditions, such as Guillain-Barré syndrome, spontaneous abortion, or even death, will occur in coincident temporal association with novel influenza vaccination. On the basis of the reviewed data, if a cohort of 10 million individuals was vaccinated in the UK, 21.5 cases of Guillain-Barré syndrome and 5.75 cases of sudden death would be expected to occur within 6 weeks of vaccination as coincident background cases. In female vaccinees in the USA, 86.3 cases of optic neuritis per 10 million population would be expected within 6 weeks of vaccination. 397 per 1 million vaccinated pregnant women would be predicted to have a spontaneous abortion within 1 day of vaccination.

PMID:
19880172
PMCID:
PMC2861912
DOI:
10.1016/S0140-6736(09)61877-8
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center